Molecular profile
- Sequence
- GLP-1/Glucagon receptor dual agonist
- Molecular Formula
- C 179 H 288 N 50 O 52
- Molecular Weight
- 3998.57 g/mol
- Synonyms
- OXM3, IBI362
Peptide research profile
Mezdutide
Mezdutide, also known as mazdutide or OXM3, is a dual agonist peptide that targets both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. This unique mechanism makes it highly effective for weight management and metabolic health improvements.…
Dosing literacy
Dosing & scaling, explained
The moderated mass amounts below are retained for comparison. Near-duplicates, mix-dependent volumes and device markings are excluded. This is educational source context—not a protocol or recommendation.
Recorded amount context
Mass amounts available for comparison
- Lower range2.5 mcgWeeks 1–4
Recorded example with no verified study backing; shown for amount literacy only.
- Low-mid range5 mcgWeeks 5–8+
Recorded example with no verified study backing; shown for amount literacy only.
- Mid range2.5 mgWeeks 1–4
Recorded example with no verified study backing; shown for amount literacy only.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
Schedule literacy
No independently verified schedule
Evidence context
No clinical amount or schedule is inferred from this material. Source verification is pending, and every displayed amount remains educational context rather than guidance.
Research best practices
Storage, handling and interpretation
Product identity
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Storage & handling
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Prepared solutions
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
Research orientation
What researchers are exploring
These themes organize the educational information currently available. Individual claims remain under source review and are not treatment claims.
- 01
Preclinical Studies
Research on Mezdutide in animal models
- 02
Clinical Trials
Human clinical trial results and findings
- 03
Advancements in Metabolic Health
Future applications in metabolic disease management
- 04
Innovation in Peptide-Based Therapies
The role of Mezdutide in advancing peptide therapeutics
- 05
Improving Quality of Life
Impact on patient well-being and health outcomes
Evidence map
What is known—and what still needs verification
Available context is organized without assigning unsupported study models or evidence grades.
- Source review pending
Preclinical Studies
Research on Mezdutide in animal models
- Source review pending
Clinical Trials
Human clinical trial results and findings
Recorded protocol library
Amounts recorded for Mezdutide
These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.
- 01
Weeks 1–4
2.5 mcg
Sign in for schedule, duration and source context.
- 02
Weeks 5–8+
5 mcg
Sign in for schedule, duration and source context.
- 03
Weeks 1–4
2.5 mg
Sign in for schedule, duration and source context.
Technical reference
Identity, limitations and unknowns
Important limitations
- Individual claims and source links have not yet completed editorial verification.
- Evidence level, applicable study model, formulation, route and population remain unassigned.
Source review
1 links awaiting verification
- Source link · pmc.ncbi.nlm.nih.govVerification pending · Source review pending